Oligodendroglioma

Martin J. Van den Bent, Michele Reni, Gemma Gatta, Charles Vecht

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.

Original languageEnglish
Pages (from-to)262-272
Number of pages11
JournalCritical Reviews in Oncology/Hematology
Volume66
Issue number3
DOIs
Publication statusPublished - Jun 2008

Fingerprint

Oligodendroglioma
temozolomide
Intracranial Pressure
Neoplasms
Seizures
Cerebrum
Adjuvant Chemotherapy
Glioma
Disease-Free Survival
Radiotherapy
Therapeutics
Recurrence
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Oligodendroglioma. / Van den Bent, Martin J.; Reni, Michele; Gatta, Gemma; Vecht, Charles.

In: Critical Reviews in Oncology/Hematology, Vol. 66, No. 3, 06.2008, p. 262-272.

Research output: Contribution to journalArticle

Van den Bent, Martin J. ; Reni, Michele ; Gatta, Gemma ; Vecht, Charles. / Oligodendroglioma. In: Critical Reviews in Oncology/Hematology. 2008 ; Vol. 66, No. 3. pp. 262-272.
@article{0e8feafa7f8141a8bc4840eb432c68ae,
title = "Oligodendroglioma",
abstract = "Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.",
author = "{Van den Bent}, {Martin J.} and Michele Reni and Gemma Gatta and Charles Vecht",
year = "2008",
month = "6",
doi = "10.1016/j.critrevonc.2007.11.007",
language = "English",
volume = "66",
pages = "262--272",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

TY - JOUR

T1 - Oligodendroglioma

AU - Van den Bent, Martin J.

AU - Reni, Michele

AU - Gatta, Gemma

AU - Vecht, Charles

PY - 2008/6

Y1 - 2008/6

N2 - Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.

AB - Oligodendrogliomas (OD) are rare, diffusely infiltrating tumors, arising in the white matter of cerebral hemispheres, and displaying better sensitivity to treatment and prognosis than other gliomas. Favorable prognostic factors are low-grade, combined loss of 1p/19q, younger age, good performance status, and frontal localization. Low-grade OD usually present with seizures, whereas high-grade tumors often present with focal deficits, increased intracranial pressure or cognitive deficits. Treatment may be deferred until progression in young patients with low-grade OD presenting with seizures only. Patients with enhancing lesions, mass effect, focal deficits or increased intracranial pressure should be treated without delay. Treatment consists of resection as extensive and as safe possible. Postoperative radiotherapy is indicated for large, unresectable, or incompletely resected tumors; focal deficits; anaplastic tumors; or enhancing lesions. Adjuvant PCV chemotherapy increased progression-free survival but does not improve survival as compared to PCV given at recurrence. Chemotherapy with either PCV or temozolomide constitutes a standard for recurrent/progressive disease.

UR - http://www.scopus.com/inward/record.url?scp=42749090116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42749090116&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2007.11.007

DO - 10.1016/j.critrevonc.2007.11.007

M3 - Article

C2 - 18272388

AN - SCOPUS:42749090116

VL - 66

SP - 262

EP - 272

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 3

ER -